Emergent BioSolutions | EBS - Чистый доход





Чистый доход Изменить Дата
Acadia Pharmaceuticals USD 3.64M 269.93M 2026-03
Akebia Therapeutics USD -12.24M 12.78M 2025-12
ALKERMES USD -66.48M 115.82M 2026-03
Alnylam Pharmaceuticals USD 205.99M 19.57M 2026-03
Amarin USD -1.22M 6.51M 2025-12
ANI Pharmaceuticals USD 29.49M 2.86M 2026-03
BioMarin Pharmaceutical USD 105.53M 152.1M 2026-03
Coherus Biosciences USD -37.64M 2.11M 2025-12
Emergent BioSolutions USD -261.3M 78.3M 2023-06
Exelixis USD 210.47M 34.06M 2026-03
Glaxosmithkline GBP 846.06M 1.87B 2025-12
Heron Therapeutics USD -2.95M 14.54M 2025-12
Ionis Pharmaceuticals USD -93M 136M 2026-03
Ironwood Pharmaceuticals USD 3.19M 457K 2024-12
Lexicon Pharmaceuticals USD -15.53M 2.76M 2025-12
Lonza CHF 426M 119M 2025-06
Merck USD -4.24B 7.2B 2026-03
Moderna USD -1.34B 517M 2026-03
Myriad Genetics USD -7.9M 19.5M 2025-12
Nektar Therapeutics USD -36.08M 978K 2025-12
Neurocrine Biosciences USD 197.9M 44.2M 2026-03
Pacira USD 2.92M 1.28M 2026-03
Pfizer USD 2.69B 4.34B 2026-03
PTC Therapeutics USD -2.81M 132.16M 2026-03
Sanofi EUR 1.61B 2.42B 2026-03
Sarepta Therapeutics USD 330.96M 743.18M 2026-03
United Therapeutics USD 274.9M 89.4M 2026-03
Vanda Pharmaceuticals USD -18.9M 13.58M 2024-12
Xoma USD -17.24M 33.23M 2024-09